Jupiter,

Great summary for the inner statistician in all of us ;) 

Concise snapshot of our  likely starting market ; diabetics with higher grade CKD; at high risk of CVD events.  And may I add, for those calculating market caps;  this is not all endof life stuff... patients in 40's and 50's, unfortunately  included.   

"CKD group:  A very high risk group that formed 10.5% of the trial population but that suffered between 15 and 24% of most adverse events (in the combined apabetalone and placebo groups).  Apabetalone provided a large benefit in this group by approximately halving the incidence rates for most events relative to the control group.  In essence, being a CKD patient approximately doubled your MACE risk in this trial and apabetalone almost halved it again, bringing it back closer in line with the nonCKD patients...  An excellent combination for an excellent result!"